Adverse prognostic impact of KIT exon 17 mutations despite negative flow cytometric measurable residual disease in pediatric acute myeloid leukemia with RUNX1::RUNX1T1

Not available.

• Publication year

  2024

• Venue

  Haematologica

• Publication date

  2024-09-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.3324/haematol.2024.286243PMID 39234860PMCID 11694115
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia

  2023cited by this paper
• Measurable residual disease in pediatric acute myeloid leukemia: a systematic review

  2021cited by this paper
• Time point‐dependent concordance and prognostic significance of flow cytometry and real time quantitative PCR for measurable/minimal residual disease detection in acute myeloid leukemia with t(8;21)(q22;q22.1)

  2021cited by this paper
• Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.

  2020cited by this paper
• Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.

  2019cited by this paper
• Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia

  2019cited by this paper
• Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.

  2019cited by this paper
• KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia

  2018cited by this paper
• The genomic landscape of core-binding factor acute myeloid leukemias

  2016cited by this paper
• Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.

  2015cited by this paper
• Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial

  2015cited by this paper
• Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.

  2014cited by this paper
• Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children

  2013cited by this paper
• Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.

  2012cited by this paper
• Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

  2010cited by this paper

• Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children's Cancer Group trial (JCCG AML-12).

  2026cites this paper
• Molecular genetics profiling of core-binding factor acute myeloid leukemia in pediatrics

  2025cites this paper
• A review of cytogenetic and molecular features in paediatric acute myeloid leukaemia

  2025cites this paper
• Multiple Hematopoietic Stem Cell Transplantations in Pediatric Acute Myeloid Leukemia: Prognostic Significance of Remission and Severe Sinusoidal Obstruction Syndrome

  2025cites this paper
• Beyond “favorable”: early molecular response and outcomes in pediatric RUNX1::RUNX1T1 AML

  2025cites this paper